Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MAZEthis companyMaze Therapeutics, Inc.	$34.25	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
ARDXArdelyx, Inc.	$2.90	-22.42×	8.42×	3.45×	-53.09×	-5941.7%	89.5%	-10.1%	-15.1%	-36.9%	-9.9%	-3.1%	1.27×	-4.92×	-1.44×	4.31×	0.0%	2	-0.11	1	D+
BIOABioAge Labs Inc.	$5.43	-5.91×	1.75×	52.85×	-3.66×	53.5%	100.0%	-1031.5%	-896.1%	-29.6%	-33.4%	-17.3%	0.02×	2.3×	-133.11×	14.24×	0.0%	3	4.79	2	C+
DMACDiaMedica Therapeutics Inc.	$9.82	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
PTCTPTC Therapeutics, Inc.	$64.60	8.85×	-29.43×	3.49×	8.75×	-1377.4%	95.9%	49.5%	39.4%	-332.5%	33.4%	6.8%	-13.19×	1.94×	5.63×	2.35×	0.0%	4	0.75	2	C
SEPNSepterna Inc	$49.50	-25.35×	3.23×	26.85×	-24.05×	-147.7%	100.0%	-175.8%	-106.4%	-12.8%	-15.8%	8.9%	0.06×	2.05×	0×	4.73×	0.0%	3	6.86	2	C
Peer median	—	-11.37×	3.23×	3.49×	-10.97×	-147.7%	95.9%	-10.1%	-15.1%	-36.9%	-15.8%	-3.1%	0.02×	1.94×	0×	4.73×	0.0%	3	4.79	2	—